AUS
NZ
UK
CA
USA
IND
Highlights
- EMVision activates new US site for pivotal emu brain scanner trial
- UCLA Health joins multi-centre validation study
- Federal grant supports regional stroke care research in Australia
EMVision Medical Devices (ASX:EMV) has advanced its pivotal emu brain scanner trial with the activation of a new site in the United States, marking another step in its global research program. The development strengthens the company’s focus on enhancing stroke diagnosis and treatment through innovative medical technology, an area of interest within ASX 200 companies.
US Validation Trial at UCLA Health
The new site at UCLA Health will play a key role in validating EMVision’s emu brain scanner. The trial is designed to evaluate the accuracy of the device compared with existing neuroimaging standards, such as CT and MRI scans. Led by a vascular and interventional neurology specialist, the study will work to assess the potential of the device in real-world stroke care settings.
In addition to UCLA, several other centres across the United States and Australia are preparing for trial participation. The multi-centre approach ensures comprehensive data collection across diverse patient groups, strengthening the evidence base for potential regulatory submissions.
The Non-Invasive Brain Scanner
The emu brain scanner is a portable, non-invasive device that uses ultra-high frequency radiofrequency technology and AI-driven algorithms. Its lightweight design aims to make stroke diagnosis faster and more accessible, particularly in urgent care scenarios. Unlike traditional imaging equipment, the device is designed for point-of-care use, potentially reducing the time taken to diagnose and initiate treatment for patients.
Previous studies involving healthy volunteers and patients with suspected stroke have provided encouraging results, leading to this large-scale validation effort.
Support for Regional Australia
Beyond the US trial, EMVision is also focusing on improving stroke care in regional Australia. The company has secured government funding to study the benefits of deploying the emu brain scanner in rural and remote areas, where access to advanced imaging technologies remains limited.
This study is aimed at exploring how telehealth-enabled devices can improve outcomes by accelerating time to diagnosis and treatment. The insights gathered will not only guide commercialisation but also help address healthcare disparities in underserved communities.
Outlook
EMVision’s trial and ongoing regional studies highlight the growing role of portable medical technologies in reshaping critical care pathways. With both international and domestic initiatives underway, the company continues to move toward broader adoption of its device in stroke management.
Frequently Asked Questions
- What is EMVision Medical Devices (ASX:EMV) currently trialling?
EMVision is trialling its emu brain scanner, a portable, non-invasive device designed to assist in rapid stroke diagnosis. - Where is the new trial site located for the emu brain scanner study?
The new trial site is at UCLA Health in the United States, as part of a larger multi-centre validation trial. - How is EMVision supporting stroke care in regional Australia?
EMVision is conducting a government-backed study to evaluate how its emu brain scanner can enhance stroke diagnosis and treatment in rural and remote communities.
